AnalyzeDirect Keqiang Zhang et al. Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy Theranostics.
Publication Date
September 2, 2026
How Analyze was Used
“To evaluate the impact of Usp22-KO on tumor growth in vivo, changes in tumor volume were measured over 4 weeks through serial CT scans. Serial lung images were reconstructed, and tumor volumes were subsequently analyzed using Analyze-15 (AnalyzeDirect, Overland Park, Kansas, USA).”
Keywords
Ubiquitin-specific peptidase (USP22), KRAS/p53-driven lung cancer, Tumor microenvironment (TME), Immune checkpoint inhibitors (ICI), Anti-PD-1 therapy
Author Affiliation(s)
City of Hope National Medical Center, Duarte, California, USA
